Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes

Archives of Iranian Medicine

Volumn 16, Issue 7, 2013, Pages 408-411

  Soveid, Mahmood ^a   Dehghani, Gholam Abbas ^a   Omrani, Gholamhossein Ranjbar ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes mellitus; Insulin; Type 1; Vanadium

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; PROTAMINE; TRIACYLGLYCEROL; VANADIUM; VANADYL SULFATE;

ABDOMINAL PAIN; ABNORMAL FECES; ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; CHEMICAL PARAMETERS; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIABETIC PATIENT; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; LONG TERM CARE; MALE; SCHOOL CHILD; SYSTEMIC DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; VANADIUM COMPOUNDS; YOUNG ADULT;

EID: 84879378699     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sakurai H. A new concept: the use of vanadium complexes in the treatment of diabetes mellitus. Chem Rec. 2002; 2: 237-248.
2. Clark TA, Deniset JF, Heyliger CE, Pierce GN. Alternative therapies for diabetes and its cardiac complications: role of vanadium. Heart Failure Reviews. 2013: 1-10. doi:10.1007/s10741-013-9380-0
3. Dehghani GA, Ahmadi S, Omrani GR. Effects of vanadyl sulphate on glucose homeostasis in severe diabetes induced by streptozotocin in rats. Indian J Med Res. 1997; 106: 481-485.
4. Yao J, Battell ML, McNeill JH. Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction. Can JPhysiol Pharmacol. 1997; 75: 83-90.
5. Cam MC, Li WM, McNeill JH. Partial preservation of pancreatic beta-cells by vanadium: evidence for long-term amelioration of diabetes. Metabolism. 1997; 46: 769-778.
6. Malabu UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G. Effects of chronic vanadate administration in the STZ-induced diabetic rat. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding. Diabetes. 1994; 43: 9-15.
7. Rosa J, Skala H. Effects of vanadate on glucose production in cultured hepatocytes isolated from rats on high saturated fat diet. Coll Antropol. 2005; 29:693-696.
8. Shafrir E, Spielman S, Nachliel I, Khamaisi M, Bar-On H, Ziv E. Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. Diabetes Metab Res Rev. 2001; 17: 55-66.
9. Yuen VG, Pederson RA, Dai S, Orvig C, McNeill JH. Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/ fa Zucker rats. Can J Physiol Pharmacol. 1996; 74: 1001-1009.
10. Daubros W, Goc A, Turyna B, Kordowiak AM. Influence of Vanadyl Sulphate [VOSO4] on Biochemical Activity and Morphology of Control and Streptozotocin-Diabetic Rat Liver Golgi Complexes. Polish Journal of Pathology. 2004; 55: 25-32.
11. Kawabe K, Yoshikawa Y, Adachi Y, Sakurai H. Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes. Life Sci. 2006; 78: 2860-2866.
12. Mohammad A, Sharma V, McNeill JH. Vanadium increases GLUT4 in diabetic rat skeletal muscle. Mol Cell Biochem. 2002; 233: 139-143.
13. Fugono J, Yasui H, Sakurai H. Improvement of diabetic states in strepto-zotocin-induced type 1 diabetic rats by vanadyl sulfate in enteric-coated capsules. JPharm Pharmacol 2005; 57: 665-669.
14. Bolkent S, Bolkent S, Yanardag R, Tunali S. Protective effect of vanadyl sulfate on the pancreas of streptozotocin-induced diabetic rats. Diabetes Res ClinPract. 2005; 70: 103-109.
15. Ahmadi S, Karimian SM, Sotoudeh M, Bahadori M, Dehghani GA. Pancreatic Islet Beta Cell Protective Effect of Oral vanadyl sulphate in Streptozotocin-induced Diabetic Rats, an Ultrastructure Study. Pakistan Journal ofBiological Sciences. 2010; 13: 1135-1140.
16. Cam MC, Rodrigues B, McNeill JH. Distinct glucose lowering and beta cell protective effects of vanadium and food restriction in streptozoto-cin-diabetes. Eur J Endocrinol. 1999; 141: 546-554.
17. Dehghani GA, Sotoodeh M, Omrani GR. Trophic effects of vanadium on beta-cells of STZ-induced insulin dependent diabetic rats & evidence for long-term relief of diabetes mellitus. Indian J Med Res. 1999; 110: 70-75.
18. Domingo JL. Vanadium and diabetes. What about vanadium toxicity? Mol Cell Biochem. 2000; 203: 185-187.
19. Goldfìne AB, Simonson DC, Folli F, Patti ME, Kahn CR. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem. 1995; 153: 217-231.
20. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes. 1996; 45: 659-666.
21. Goldfìne AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, et al. Kahn CR. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism. 2000; 49: 400-410.
22. Cros GH, Cam MC, Serrano JJ, Ribes G, McNeill JH. Long-term antidiabetic activity of vanadyl after treatment withdrawal: Restoration of insulin secretion?Mol Cell Biochem. 1995; 153: 191-195.
23. Domingo JL. Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects. Biol Trace Elem Res. 2002; 88: 97-112.
24. Meyerovitch J, Farfel Z, Sack J, Shechter Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J Biol Chem. 1987; 262: 6658-6662.
25. Srivastava AK. Anti-diabetic and toxic effects of vanadium compounds. Mol Cell Biochem. 2000; 206: 177-182.
26. Djordjevic C. Antitumor activity of vanadium compounds. Met Ions Biol Syst. 1995; 31: 595-616.
27. Baquer NZ, Kumar P, Taha A, Kale R, Cowsik S, McLean P. Metabolic and molecular action of Trigonella foenum-graecum (fenugreek) and trace metals in experimental diabetic tissues. Journal of Biosciences. 2011; 36: 383-396.
28. Smith DM, Pickering RM, Lewith GT. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. QJM. 2008; 101: 351-358.
29. Majithiya JB, Balaraman R, Giridhar R, Yadav MR. Effect of bis[curcumino]oxovanadium complex on non-diabetic and streptozoto-cin-induced diabetic rats. Journal of Trace Elements in Medicine and Biology. 2005; 18: 211-217.
30. Zhang SQ, Zhong XY, Lu WL, Zheng L, Zhang X, Sun F, et al. Zhang Q. Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. Journal of Inorganic Biochemistry. 2005; 99: 1064-1075.
31. Cam MC, Cros GH, Serrano JJ, Lazaro R, McNeill JH. In vivo antidiabetic actions of naglivan, an organic vanadyl compound in streptozoto-cin-induced diabetes. Diabetes Research and Clinical Practice. 1993; 20: 111-121.
32. Karmaker S, Saha TK, Yoshikawa Y, Yasui H, Sakurai H. A novel drug delivery system for type 1 diabetes: insulin-mimetic vanadyl-poly(gamma-glutamic acid) complex. J Inorg Biochem. 2006; 100: 1535-1546.